Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supplements, and urinary tract generics, as well as management and consultancy services. The company was incorporated in 2017 and is based in Ahmedabad, India.
| Current Price | ₹1,214.00 |
|---|---|
| Market Cap | ₹6,072 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 50.1 |
| Return on Equity | 13.68% |
| 52-Week Range | ₹706.00 – ₹1,599.00 |
| Beta (1Y) | 0.21 |
| Revenue | ₹180 Cr |
|---|---|
| Net Profit | ₹30 Cr |
| EPS (Basic) | ₹6.61 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
1. Pharmaceuticals-100%
SENORES PHARMACEUTICALS LIMITED is trading at ₹1,214.00, with a market capitalisation of ₹6,072 Cr.
SENORES PHARMACEUTICALS LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
SENORES PHARMACEUTICALS LIMITED has a P/E of 50.1 and a return on equity of 13.68%.
In Q1 FY27, SENORES PHARMACEUTICALS LIMITED reported revenue of ₹180 Cr and net profit of ₹30 Cr, with basic EPS of ₹6.61 (consolidated, parsed from the company's exchange filing).